Announced Thu, 25 Jun · 22:39 IST
USFDA issues 7 observations to Dr. Reddy's biologics facility in Hyderabad
Regulatory & Legal View source PDF
DRREDDY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.7%1-day move
₹1349.50
prior close
₹1388.40
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.1+1.2+0.6+1.1+0.7-0.8-0.4+1.6+1.1+0.1-9.5———
Up moveDown movePending
AI summary
The USFDA completed a Pre-License Inspection at Dr. Reddy's biologics manufacturing facility in Bachupally, Hyderabad, from June 16 to June 25, 2026. The company received a Form 483 with seven observations, which it plans to address within the stipulated timeline. This follows earlier inspections disclosed in October 2023 and September 2025.
Likely market impact
Form 483 observations may delay approvals from this facility. Addressable, no warning letter yet; near-term biologics pipeline impact possible.